Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of “Hold” by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given an average rating of “Hold” by the ten brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $9.33.

Several analysts recently commented on FULC shares. Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $22.00 to $3.00 in a research note on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $10.00 to $2.00 in a research report on Thursday, September 12th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. National Bank of Canada FI boosted its stake in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after buying an additional 4,000 shares in the last quarter. Capstone Investment Advisors LLC purchased a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth $68,000. Profund Advisors LLC purchased a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth $68,000. Renaissance Technologies LLC acquired a new position in shares of Fulcrum Therapeutics during the 2nd quarter worth $82,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Fulcrum Therapeutics by 66.7% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock valued at $112,000 after purchasing an additional 4,766 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

FULC opened at $3.57 on Tuesday. Fulcrum Therapeutics has a one year low of $2.87 and a one year high of $13.70. The stock has a market capitalization of $221.89 million, a P/E ratio of -2.23 and a beta of 2.21. The business’s 50-day simple moving average is $7.06 and its 200-day simple moving average is $7.48.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.93. The company had revenue of $80.00 million for the quarter, compared to analyst estimates of $80.00 million. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. During the same quarter in the previous year, the company posted ($0.38) earnings per share. On average, equities research analysts forecast that Fulcrum Therapeutics will post -0.28 EPS for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.